• event_id: 2026-06-16-biotech-capital-cycle-phase-0a-refresh

Context: Phase 0a qualitative refresh, 12 days after open. Summaries stale (2026-06-12 precompute); no numerics per Phase 0a rule.

Key event since 2026-06-04: the SpaceX direct-listing debuted on June 12 — the exact mega-IPO event that was cross-linked from day one as the opposite-sign sibling of this thesis. The biotech-capital-cycle frame always noted that SpaceX drains liquidity while a healthy biotech issuance regime returns it. That mechanic is now live.

Thesis update (qualitative):

The SpaceX debut creates a digestion window estimated at 4–8 weeks. Institutional allocation, dealer balance-sheet capacity, and retail risk appetite all get partially claimed by secondary SpaceX trading activity, reducing near-term bandwidth for the biotech IPO queue. This does not break the cycle — the structural drivers (capital deployed into biotechs during the Q1–Q2 2026 issuance wave still flows downstream to reagent/CRO/tool spend regardless of SpaceX) — but it pushes the realistic timing for the next wave of biotech deals and for XBI to reclaim its trend.

Domino board update (qualitative, not numeric):

• Domino #0 (theme front-run): no change in character — mid-cap tools/CROs remain the early movers.
• Domino #1 (THE GATE — capital markets open): the SpaceX event is a near-term headwind on the sentiment/issuance leg of this domino. The fundamental spending leg (reagent/CRO bookings fed by the Q1–Q2 IPO cash) is unaffected. Expect the gate to stay half-open through late July.
• Domino #3 (CRO book-to-bill): MEDP Q2 print (~late July 2026) is the first clean confirmation window — now lands squarely inside the post-SpaceX digestion period, making it doubly important as an escalation catalyst.

What did NOT change:

• The laggard quality thesis (TMO/DHR/MEDP/RGEN — un-re-rated quality waiting for the second leg) is intact.
• MEDP remains the single highest-conviction name (cheapest, fastest-growing, no debt, direct cycle proxy).
• The SDGR software-moat optionality and the ABCL/GENB barbell framework are unchanged.
• The XBI gate as the master trigger is unchanged.

Narrative arc: escalation arc, now with a SpaceX-induced pause. Positioning: hold laggard quality, don't chase extended mid-caps, let MEDP Q2 speak before rotating in size.

No new tickers, watchlist changes, or ACTIVE.json updates in this pass. Prose and watch-fors updated in README; numerics deferred to Phase 0b.